Clinical Trial Search

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: PFS (Progression Free Survival) — NA; 18.9 Months — p=<0.0001

Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014

Primary: Number of Subjects With Adverse Events — 199 Participants

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Overall Response Rate — 6; 7 Participants

Primary: Overall Response Rate — 77.8 % of participants with response by PI

Primary: Overall Response Rate (ORR) — 7.1 percentage of participants

Primary: Overall Response Rate — 81.8 Percentage

Primary: Participants With Objective Response — 0; 1; 13 Participants

Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells

Primary: ORR (Overall Response Rate) — 46 Percentage of Participants

Primary: Response Rate — 11; 6 participants

Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants

Primary: Maximum-tolerated Dose of Dinaciclib When Given in Combination With Ofatumumab, Defined as a Dose Level Where at Most One of 6 Evaluable Patients Has a Dose Limiting…

Primary: Response Rate — 55.2 percentage

Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants

Primary: Total Number of Adverse Events. — 2 Adverse events

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Number of Patients With Complete Response — 14; 3 participants

Primary: Major Response Rate (MRR) as Assessed by the Independent Review Committee — 69.8 Percentage of participants — p=<0.0001

Primary: Overall Response — 11; 23; 4; 5 participants

Primary: Complete and Overall Response Rate — 50.0; 33.3; 93.8; 96.7 percentage of patients